DE60232660D1 - Humane dr4-antikörper und deren anwendungen - Google Patents

Humane dr4-antikörper und deren anwendungen

Info

Publication number
DE60232660D1
DE60232660D1 DE60232660T DE60232660T DE60232660D1 DE 60232660 D1 DE60232660 D1 DE 60232660D1 DE 60232660 T DE60232660 T DE 60232660T DE 60232660 T DE60232660 T DE 60232660T DE 60232660 D1 DE60232660 D1 DE 60232660D1
Authority
DE
Germany
Prior art keywords
antibodies
human
applications
kits
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60232660T
Other languages
German (de)
English (en)
Inventor
Anan Chuntharapai
Kyung Jin Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE60232660D1 publication Critical patent/DE60232660D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60232660T 2001-07-03 2002-06-29 Humane dr4-antikörper und deren anwendungen Expired - Lifetime DE60232660D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30322001P 2001-07-03 2001-07-03
PCT/US2002/020712 WO2003066661A2 (en) 2001-07-03 2002-06-29 Human dr4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DE60232660D1 true DE60232660D1 (de) 2009-07-30

Family

ID=27734188

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60232660T Expired - Lifetime DE60232660D1 (de) 2001-07-03 2002-06-29 Humane dr4-antikörper und deren anwendungen

Country Status (13)

Country Link
US (2) US7252994B2 (enExample)
EP (2) EP2192130A1 (enExample)
JP (1) JP4509570B2 (enExample)
AT (1) ATE433996T1 (enExample)
AU (2) AU2002366430B2 (enExample)
CA (1) CA2451680C (enExample)
CY (1) CY1110505T1 (enExample)
DE (1) DE60232660D1 (enExample)
DK (1) DK1409544T3 (enExample)
ES (1) ES2328234T3 (enExample)
IL (1) IL159527A0 (enExample)
PT (1) PT1409544E (enExample)
WO (1) WO2003066661A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) * 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
CN1610696A (zh) * 2001-12-20 2005-04-27 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
ES2239886B1 (es) * 2003-11-05 2006-12-16 Universidad De Barcelona Metodo y aparato para la determinacion de la viabilidad celular.
AU2012200602B2 (en) * 2004-08-06 2012-11-08 Genentech, Inc. Assays and methods using biomarkers
MX2007001469A (es) 2004-08-06 2007-03-26 Genentech Inc Ensayos y metodos que utilizan biomarcadores.
WO2006017859A2 (en) * 2004-08-06 2006-02-16 Genentech, Inc. Assays and methods using biomarkers
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
AU2006279618A1 (en) 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2626361C (en) * 2005-10-16 2016-08-16 David Wallach Pharmaceutical compositions and diagnostic methods for inflammatory skin diseases, disorders or conditions
EP1948614A2 (en) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
ATE522518T1 (de) 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
US9044457B2 (en) 2010-06-16 2015-06-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-DR4 agonist antibodies
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
EP2992013B1 (en) 2013-04-29 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
IL251822B2 (en) 2014-10-29 2023-03-01 Teva Pharmaceuticals Australia Pty Ltd Variants of interferon alpha-2-b
CA3003033A1 (en) 2015-10-30 2017-05-04 Galaxy Biotech, Llc Highly potent antibodies binding to death receptor 4 and death receptor 5
AU2016363770A1 (en) 2015-12-01 2018-06-28 Genmab B.V. Anti-DR5 antibodies and methods of use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905669D0 (en) * 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
AU1368292A (en) 1991-03-11 1992-10-06 Sheila Drover Murine monoclonal antibodies recognizing polymorphic determinants of hla
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
ATE285475T1 (de) 1994-02-04 2005-01-15 Bio Merieux Msrv1 virus der mit multipler sklerose verbunden ist, seine nukleären bestandteile und verwendungen
EP1666591B1 (en) 1995-06-29 2011-03-23 Immunex Corporation Cytokine that induces apoptosis
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
CA2266439C (en) 1996-10-25 2009-06-16 Human Genome Sciences, Inc. Neutrokine .alpha.
CA2274987C (en) 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
EP1012274B2 (en) 1997-01-28 2011-06-15 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
ATE352618T1 (de) 1997-03-17 2007-02-15 Human Genome Sciences Inc Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
ES2284203T5 (es) 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
AU7126498A (en) 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
WO1999002653A1 (en) 1997-07-11 1999-01-21 Trustees Of The University Of Pennsylvania Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
WO1999004001A1 (en) 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
WO1999007738A2 (en) 1997-08-06 1999-02-18 Regeneron Pharmaceuticals, Inc. Human orphan receptor ntr-1
JP2001514888A (ja) 1997-08-15 2001-09-18 アイドゥン ファーマシューティカルズ， インコーポレイテッド Ｔｒａｉｌレセプター、これをコードする核酸、およびその使用方法
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
JP2002500877A (ja) * 1998-01-26 2002-01-15 ジェネンテク・インコーポレイテッド 細胞死レセプター４（ｄｒ４）に対する抗体及びその使用
US20040120947A1 (en) * 1998-01-26 2004-06-24 Genentech, Inc. DR4 antibodies and uses thereof
US20040180049A1 (en) * 1998-01-26 2004-09-16 Genentech, Inc. DR4 antibodies and uses thereof
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
ES2395693T3 (es) 1998-06-12 2013-02-14 Genentech, Inc. Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la fabricación de los mismos
PT1181319E (pt) * 1999-05-28 2009-07-14 Genentech Inc Anticorpos quiméricos contra dr4 e suas utilizações
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
WO2002094880A1 (fr) * 2001-05-18 2002-11-28 Kirin Beer Kabushiki Kaisha Anticorps anti-trail-r
CA2446723C (en) 2001-05-25 2014-01-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
RU2313368C2 (ru) 2001-11-01 2007-12-27 Ю Эй Би Рисерч Фаундейшн Комбинации антител, обладающих селективностью по отношению к рецептору лиганда, индуцирующему апоптоз, ассоциированный с фактором некроза опухоли, и других терапевтических средств
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
WO2003042367A2 (en) 2001-11-14 2003-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors

Also Published As

Publication number Publication date
CA2451680A1 (en) 2003-08-14
ATE433996T1 (de) 2009-07-15
US20040147725A1 (en) 2004-07-29
US20080233646A1 (en) 2008-09-25
IL159527A0 (en) 2004-06-01
PT1409544E (pt) 2009-09-16
ES2328234T3 (es) 2009-11-11
EP1409544A4 (en) 2005-11-09
DK1409544T3 (da) 2009-10-26
JP2005517021A (ja) 2005-06-09
AU2008260311A1 (en) 2009-01-15
US7252994B2 (en) 2007-08-07
AU2002366430B2 (en) 2008-09-18
HK1065323A1 (en) 2005-02-18
EP1409544A2 (en) 2004-04-21
WO2003066661A3 (en) 2003-11-27
AU2002366430A1 (en) 2003-09-02
WO2003066661A2 (en) 2003-08-14
CY1110505T1 (el) 2015-04-29
JP4509570B2 (ja) 2010-07-21
EP1409544B1 (en) 2009-06-17
CA2451680C (en) 2011-04-19
EP2192130A1 (en) 2010-06-02
US7744881B2 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
DE60232660D1 (de) Humane dr4-antikörper und deren anwendungen
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
CY1109151T1 (el) Αντισωματα dr4 και χρησεις αυτων
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
ATE465257T1 (de) Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
WO2004011611A3 (en) Taci antibodies and uses thereof
NO20061736L (no) Krystallform av epotilon B
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
ATE325789T1 (de) Aminocyclohexylether-verbindungen und deren verwendung
ATE420097T1 (de) Substituierte sapogenine und ihre verwendung
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
DE60335610D1 (de) Neoplasma-spezifische antikörper und deren verwendungen
ID25478A (id) Agonis 5-ht1f
EP1498145A4 (en) LURE FOR THE TREATMENT AND / OR PREVENTION OF ALLERGIC DISEASE ASSOCIATED WITH CYTOKINE TH2, MUTANT PROTEIN GATA3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
ES2176642T3 (es) Utilizacion de la sulbutiamina para la obtencion de composiciones farmaceuticas utiles en el tratamiento de ciertos t rastornos psicomotores y psicointelectuales.
DE60336504D1 (de) 4-hydroxypiperidin-derivate zur verwendung als antimycobakterielle mittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition